Sullivan, and K
Its dual impact on neurological and physiological pathways makes it relevant in a wide range of studies
(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
When successful, they can provide us with clues that could lead to the next treatment breakthrough. Researchers are now developing a longer study to evaluate the effects of GSH nasal therapy, given over three months, on PD symptoms.
Summary If you are deficient in vitamin B12, then the injections are very effective at raising your blood levels
Supplementary Materials Data Availability Statement The datasets used and/or analysed in the current study are available upon reasonable request
